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Abstract
Background: Glutamate excitotoxicity contributes to oligodendrocyte and tissue damage in multiple sclerosis (MS).
Intriguingly, glutamate level in plasma and cerebrospinal fluid of MS patients is elevated, a feature which may be
related to the pathophysiology of this disease. In addition to glutamate transporters, levels of extracellular
glutamate are controlled by cystine/glutamate antiporter xc
-, an exchanger that provides intracellular cystine for
production of glutathione, the major cellular antioxidant. The objective of this study was to analyze the role of the
system xc
- in glutamate homeostasis alterations in MS pathology.
Methods: Primary cultures of human monocytes and the cell line U-937 were used to investigate the mechanism
of glutamate release. Expression of cystine glutamate exchanger (xCT) was quantified by quantitative PCR, Western
blot, flow cytometry and immunohistochemistry in monocytes in vitro, in animals with experimental autoimmune
encephalomyelitis (EAE), the animal model of MS, and in samples of MS patients.
Results and discussion: We show here that human activated monocytes release glutamate through cystine/
glutamate antiporter xc
- and that the expression of the catalytic subunit xCT is upregulated as a consequence of
monocyte activation. In addition, xCT expression is also increased in EAE and in the disease proper. In the later,
high expression of xCT occurs both in the central nervous system (CNS) and in peripheral blood cells. In particular,
cells from monocyte-macrophage-microglia lineage have higher xCT expression in MS and in EAE, indicating that
immune activation upregulates xCT levels, which may result in higher glutamate release and contribution to
excitotoxic damage to oligodendrocytes.
Conclusions: Together, these results reveal that increased expression of the cystine/glutamate antiporter system xc
-
in MS provides a link between inflammation and excitotoxicity in demyelinating diseases.
Background
Multiple sclerosis (MS) is a chronic, degenerative disease
of the CNS, which is characterized by focal lesions with
inflammation, demyelination, infiltration of immune cells,
oligodendroglial death and axonal degeneration [1-3]. MS
is typically considered as a primary inflammatory disease
in the early, relapsing phase which progresses to a second-
ary, progressive stage that is characterized by a diminished
inflammatory activity and global brain atrophy [4].
Oligodendroglial death and demyelination can occur
through glutamate excitotoxicity [5,6], a phenomenon
that takes place when an excessive amount of glutamate
overactivates ionotropic glutamate receptors (iGluRs).
Several observations have linked glutamate excitotoxicity
with MS demyelination. First, experimental autoimmune
encephalitis (EAE), an animal model for MS, is amelio-
rated by AMPA and kainate iGluR antagonists, improv-
ing oligodendrocyte loss and demyelination without
affecting immune reaction [7-9]. And second, the infu-
sion of glutamatergic agonists into rabbit optic nerve
leads to inflammation, oligodendrocyte loss, demyelina-
tion, and axonal damage, reminding these characteristics
those typical lesions in MS [10].
Data supporting the excitotoxic hypothesis in MS
include the report of higher glutamate levels in MS, both
at CNS and peripheral blood. Glutamate is increased in
cerebrospinal fluid (CSF) from MS patients with acute
lesions, whereas in silent ones glutamate is similar to
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lesions and in normal-appearing white matter in MS
patients [12]. Finally, glutamate plasma levels are also
increased in relapsing MS patients [13]. Together, these
data point to an implication of glutamate excitotoxicity
in MS pathology [14,15].
Extracellular glutamate increase in the CNS may origi-
nate from brain blood barrier breakage during pathologi-
cal conditions [16]. In blood, monocytes are able to
release glutamate, but not lymphocytes [13]. Monocytes
participate in the regulation of intrathecal inflammation
observed in MS, and constitute the major cell type in the
perivascular infiltrates that are characteristic of MS. In
addition, CD11b
+CD115
+ly-6C
high monocytes are precur-
sors of CNS dendritic cells and macrophages in EAE
lesions, being dynamically regulated during the course of
EAE and accumulating in blood immediately prior to
clinical relapses [17]. Thus, monocytes contribute to the
pathological-anatomical features in the CNS of MS
patients [18] and are an attractive tool for understanding
some of the CNS alterations that occur in MS. In addi-
tion, their easily follow-up from blood constitutes a use-
ful characteristic to use these cells as biomarkers for MS.
We have therefore analyzed the role of monocytes in the
alteration of glutamate homeostasis in MS pathology. One
of the regulators of extracellular glutamate is the cystine/
glutamate antiporter [19], also termed system xc
-, a hetero-
dimer composed of two subunits xCT and 4F2hc. The
xCT light chain confers the specificity of amino acid trans-
port, whereas the ubiquitously expressed 4F2hc is com-
mon to other amino acid transport and is required for
membrane expression of xCT. The cystine/glutamate anti-
porter is a chloride-dependent, sodium-independent trans-
porter, whose main function is to provide cystine for
antioxidant glutathione synthesis [20]. We demonstrated
that activation of human monocytes induces glutamate
release through system xc
- and an increase in the expres-
sion of its catalytic subunit xCT. Moreover, we provide
evidence that xCT expression is increased in monocyte-
macrophages-microglia lineage in EAE and MS, both at
CNS and peripheral blood, suggesting a link between glu-
tamate excitotoxicity and inflammation in MS.
Methods
Human samples
Peripheral blood for RNA expression studies was
obtained from the Neurology Service of the Hospital of
Basurto. Healthy controls matched by sex and age were
recruited at the University of the Basque Country. Char-
acteristics of peripheral blood samples are described in
Table 1. All the MS patients used in this study suffered
the relapsing form of the disease (R-MS), which included
relapsing-remitting (RR) and secondary-progressive (SP)
subtypes. Thirty five per cent of all the patients were
under long term treatment with immune-suppressors.
Among R-MS patients, 24 were experiencing a clinical
relapse and were not being treated with steroids at the
time of blood sampling. All subjects gave informed con-
sent to participate in the study. The study was approved
by the local ethical committee.
For RNA expression studies, postmortem optic nerve
samples from 16 long-standing MS patients and 12 con-
trol subjects (who died from non-neurological diseases)
were obtained at autopsy under the management of the
Netherlands Brain Bank. These samples have been pre-
viously characterized ([21]; see Table 2). MS samples
were classified according to clinical data together with
macroscopic tissue analysis as normal appearing
(NAON) or damaged optic nerves (DON).
For immunohistochemistry studies, additional postmor-
tem spinal cord samples from MS and control subjects
were obtained at autopsy from the Netherlands Brain
Bank. Characteristics of spinal cord samples are described
in Table 3. Frozen tissue was kept at -80°C until use.
For comparisons, all MS samples were matched with
control samples for sex, age and post-mortem delay.
Human PBMC, monocyte and U-937 cell line culture
Blood was taken into heparin-coated tubes and periph-
eral blood mononuclear cells (PBMCs) were isolated by
centrifugation over Ficoll-Paque PLUS (GE Healthcare).
For flow cytometry analysis PBMCs were plated at 1.5 ×
10
6 cells per ml in complete RPMI media with GlutaMax
and 25 mM HEPES (Gibco), and supplemented with 4.5
g/l glucose, 1 mM sodium pyruvate, 10% heat-inactivated
FBS and 1% penicillin-streptomycin. Monocytes were
purified from isolated PBMCs by MACS using the Mono-
cyte Isolation Kit II (Milteny Biotec) following manufac-
turer’s instructions. Cells were plated at 0.5 × 10
6 cells
per ml in complete RPMI media for 72 h. Then, the day
before glutamate release experiments media was changed
to DMEM with 1% of heat-inactivated FBS and 1% of
penicillin-streptomycin. Human U-937 monocytic cell
Table 1 Characteristics of human blood samples
Leukocytes
Gender F/M (n) Age (Mean ± SD) RR-SP
MS in remission 25/3 36.07 ± 8.48 (20-8)
Range
(20 - 51)
MS in relapse 19/5 33.15 ± 7.57 (21-3)
Range
(19 - 50)
Controls 20/5 33.64 ± 8.69
Range
(19 - 51)
F, female; M, male; RR, relapsing-remitting MS; SP, secondary-progressive MS.
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RPMI media supplemented as before. Drugs were added
30 min before cell activation by LPS (1 μg/ml; Escherichia
coli O11:B4; Sigma-Aldrich), and 48 h after, cells and cul-
ture supernatants were collected for experiments.
Induction and treatment of acute and chronic EAE
Rats (Male Lewis rats, 8 week-old weighing 200-220 g)
were injected subcutaneously in both hind feet with inocu-
lum containing 100 μg of guinea pig myelin basic protein
(Sigma) diluted in water, emulsified in equal volumes of
Table 2 Clinical characteristics of human optic nerve samples
Reference Code Gender Age PMD (hours) Duration of MS (years) MS type Optic Nerve Alterations
MS Samples
MS1 98-176 M 83 7:05 52 PP No
MS2 99-054 F 58 8:10 20 SP Yes
MS3 98-185 F 70 8:55 19 PP Yes
MS4 98-158 F 76 16:31 53 SP Yes
MS5 98-087 F 55 7:35 > 11 SP No
MS6 98-179 F 60 8:50 36 PP Yes
MS7 99-062 F 79 10:00 44 PP No
MS8 99-025 F 64 7:45 35 SP Yes
MS9 98-066 F 75 4:50 > 27 PP/SP No
MS10 01-018 F 48 8:10 8 SP No
MS11 01-003 M 69 10:00 34 PP Yes
MS12 99-119 F 38 5:15 10 RR No
MS13 00-024 F 52 8:25 16 PP/SP Yes
MS14* 99-109 M 70 6:25 22 SP Yes
MS15* 99-121 M 51 7:50 29 SP Yes
MS16* 99-066 M 69 16:45 46 PP No
Control Samples
C1, 14,16 98-101 M 72 6:45
C2,5 98-125 F 58 6.15
C3 98-104 F 74 7:25
C4 98-051 F 94 16:50
C6 98-061 F 64 6:00
C7 98-042 F 79 9:45
C8 98-148 F 54 5:35
C9 98-112 F 84 9:20
C10, 13 00-050 F 52 6:50
C11 00-090 M 70 7:45
C12 00-025 F 41 13:30
C15 98-127 M 56 5:25
Optic nerve alterations consisted of macroscopic plaques, atrophy and/or optic neuritis.
Abbreviations: Reference, Netherlands Brain Bank bar-coded numbers; A, microarrays; qPCR, real-time quantitative PCR; IH, immunohistochemistry; C, control; MS,
multiple sclerosis; M, male; F, female; PMD, postmortem delay; PP, primary progressive; SP, secondary progressive; RR, relapsing remitting. * These samples have
been used only for immunohistrochemistry
Table 3 Characteristics of human spinal cord samples
Spinal Cord
NBB reference Gender Age Neuropathology Postmortem time (h)
MS 99-109 Male 70 MS with no active plaques 6:25
99-119 Female 38 MS with active plaques 5:15
99-121 Male 51 MS 7:50
00-024 Female 52 MS 8:25
Controls 00-025 Female 41 13:30
00-050 Female 52 6:50
00-090 Male 70 7:45
02-008 Male 62 9:35
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500 μg of heat-inactivated M. tuberculosis H37Ra (DIFCO
Laboratories). The neurological deficits started 10 days
postimmunization (dpi), peaked after 14 days and remitted
by 20 dpi. Neurological impairment was monitored and
scored daily according to the following scale ranging from
0 to 8: 0, normal; 1, flaccid tail; 2, tail paralysis; 3, loss of
muscle tone in hindlimbs; 4, hindlimbs hemiparalysis; 5,
complete hindlimbs paralysis; 6, moderate paraparesis; 7,
tetraparalysis; 8, death. The tissues and samples examined
in this study were obtained at 14 dpi from rats showing a
neurological score between 3 and 6.
Chronic, relapsing EAE was induced in C57BL/6 mice
by immunization with 300 μl of MOG(35-55) (200 μg;
Sigma, Barcelona, Spain) in incomplete Freund’s adjuvant
supplemented with 8 mg/ml Mycobacterium tuberculosis
H37Ra. Pertussis toxin (500 ng; Sigma) was injected on
the day of immunization and again two days later. Neuro-
logical impairment was monitored as in acute EAE. Mice
were sacrificed at 20 days after immunization, when maxi-
mal motor symptoms were detected (see Additional file 1,
Figure S1).
Measurement of glutamate release and glutathione
Glutamate release from U-937 and human primary
monocytes was monitored by an enzymatic assay based
on the activity of the enzyme L-glutamate dehydrogenase
(15 U/ml; Sigma-Aldrich) as previously described [13,22].
Glutamate was oxidized by L-glutamate dehydrogenase
in the presence of 1 mM NADP
+ to a-ketoglutarate with
the formation of NADPH and fluorescence emission at
430 nm (excitation light 335 nm). Release was quantified
in reference to standard curves constructed with exogen-
ous glutamate. In each assay, 20 μl of culture supernatant
were used in a final volume of 300 μl.
Intracellular reduced glutathione (GSH) levels were
determined using the QuantiChrom™ GSH Assay Kit
(BioAssay Systems) according to the instructions of the
manufacturer. Briefly, control and LPS-treated U-937 cells
were harvested, rinsed in cold PBS and homogenized by
sonication in a solution containing 50 mM phosphate
(pH = 6) and 1 mM EDTA. Lysates were centrifuged at
10,000 g for 10 min at 4°C and supernatant collected for
measurement of GSH. The method comprises a colori-
metric reaction of GSH with 5,5’-dithiobis(2-nitro-benzoic
acid), which yields a yellow product. Optical density was
measured at 415 nm in a plate reader.
RNA isolation and real-time quantitative PCR (qPCR)
For leukocyte isolation, blood samples from MS and
controls were collected in K3EDTA and kept not longer
than 6 h at 4°C for avoiding changes in the RNA expres-
sion profile. Blood was centrifuged at 300 × g during
10 min and then, the plasma was removed. Red cells
were lysed with a buffer containing 155 mM NH4CL,
01.mM EDTA and 10 mM KHCO3, pH 7.4. The blood-
buffer solution was centrifuged at 300 × g during
10 min and the pellet was washed twice. The end result-
ing pellet of leukocytes was stored at -80°C until use.
Total RNA was isolated from U-937, rat optic nerve,
and human optic nerve and leukocytes using TRIzol
Reagent (Invitrogen) according to manufacturer’s guide-
lines. Subsequently, 2 μg of RNA were retrotranscribed
into cDNA using SuperScript III retrotranscriptase
(200 U/μl; Invitrogen) and random hexamers as primers
following manufacturer’s instructions.
Gene expression levels were analyzed using qPCR. Pri-
mers were designed with PrimerExpress software
(Applied Biosystems), and their sequences and gene
accession numbers are provided in Additional file 2,
Table S1. qPCR reactions were carried out as previously
described [21] using SYBRGreen (Invitrogen) as the
fluorescent reporter dye in an ABI PRISM 7000 Sequence
Detection System instrument (Applied Biosystems).
qPCR products were subjected to a dissociation protocol
to ensure that a single product of the expected melting
temperature was obtained. mRNA expression level of a
given sample was calculated from a standard curve of
stock cDNA obtained from the same tissue. Then, a nor-
malization factor was calculated for each sample by GeN-
orm v.3.4 software based on the expression levels of 4
h o u s e k e e p i n gg e n e sf o rh u m a ns a m p l e s( 1 8 sr i b o s o m a l
RNA, HRPT-1, b-2 microglobulin and cyclophilin A),
and 3 genes for rat samples (18s ribosomal RNA, cyclo-
philin A and GAPDH) [23]. Expression level of each sam-
ple was divided by this normalization factor. Data are
expressed as fold change in expression compared to the
mean of the matched controls. The relative abundance of
the different transporters was determined by using the
ΔCt method (see User Bulletin 2; Applied Biosystems).
Western blotting, flow cytometry and
immunohistochemistry
Western blot analysis of cystine/glutamate antiporter
expression was done in U-937 cell cultures and in rat and
mice spinal cord homogenates by conventional SDS-
PAGE polyacrylamide electrophoresis as described pre-
viously [24]. The system xc
- was revealed with antibodies
against the catalytic subunit xCT (0.25 μg/ml; ab37815;
AbCam). Densitometric analysis was performed using the
NIH Image program (n = 3 in triplicate).
xCT expression in human blood monocytes was ana-
lyzed by flow cytometry. PBMCs were stained using an
antibody to CD14 conjugated to PE (BD Pharmigen), and
an antibody to the intracellular epitope of xCT (2.1 μg/ml;
ab37815; AbCam) conjugated to FITC. IgG (Sigma) was
used as isotype control for xCT antibody. Extracellular
staining was done in PBS buffer containing BSA, and for
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buffer. Acquisition was performed in BSA with PBS buffer,
using a Coulter EPICS Elite flow cytometer. Data were
analyzed using the WinMDI v 2.9 software. Density plots
were used for gating CD14
+ cells in PBMC populations,
and then histograms for xCT-FITC were opened. The geo-
metric mean of the fluorescence was used for statistical
analysis.
xCT protein expression in rat and human spinal cord
was examined by double immunofluorescence. Animals
were deeply anesthetised with chloral hydrate (500 mg/kg,
i.p.) and transcardially perfused with 0.1 M sodium phos-
phate buffer (PB), pH 7.4, followed by 4% paraformalde-
hyde (PFA) in the same buffer. After extracting spinal
cord, tissue was postfixed 2 h in 4% PFA in PB and subse-
quently dehydrated in PBS containing 20% sucrose. Tissue
was included in Tissue-tek resin (Sakura) in a Frigocut
2800 E cryostat (Leica) and frozen. Serial sections of
10 μm from both rat and human spinal cords were incu-
bated with monoclonal antibodies against CD68 (1:50;
DakoCytomation) for human monocyte-macrophage
staining, and OX-42 (1:50; Serotec) for rat macrophage-
microglia staining. Next, samples were incubated with
anti-xCT antibody (5 μg/ml; ab37815; AbCam). Appropri-
ate fluorescent secondary antibodies (Invitrogen) were
used in each case. In human samples, Hoechst 33258
labeling (5 μg/ml, Sigma) was used for cell nucleus stain-
ing. Control staining was done in the absence of primary
antibodies and by preincubating with peptide (ab93079;
Abcam) and gave no labeling (Additional file 3, Figure S2).
The same results were obtained with antibodies to xCT
from Novus (NB300-317) and the staining with this anti-
body also disappears after preincubation with Novus pep-
tide (NB300-317PEP) (data not shown). Images were
taken by Olympus Fluoview FV500 and Leica LCS SP2
AOBs confocal microscopes.
Statistical analysis
Data are expressed as mean ± SEM. Statistical analysis
was performed using unpaired Student t test or
ANOVA as appropriate. Correlation between xCT
mRNA and EAAT2 or CD8 mRNA expression in
human optic nerve was assessed by Pearson’s correlation
test.
Results
Human monocytes release glutamate through cystine/
glutamate antiporter
We have previously demonstrated that activation of U-937
monocytes induces glutamate release [13]. So, we now
analyzed the mechanism of glutamate release in U-937
cells as well as in peripheral blood monocytes in vitro.
LPS-activated U-937 monocytes (LPS 1 μg/ml, 48 h)
showed a significant increase in glutamate levels (n =4 ;
p < 0.001; Figure 1A), as previously described [13]. Incu-
bating cells with the non competitive blocker of glutamate
transporters DL-threo-beta-benzyloxyaspartate (TBOA;
100 μM) or with dihydrokainate (DHK; 1 mM), a selective
inhibitor of EAAT2 glutamate transporter, did not block
LPS-induced glutamate release by monocytes (n =4 ;
Figure 1A), excluding any role of glutamate transporters in
such glutamate release. In contrast, incubating cells with
aminoadipic acid (AAA, 1 mM), an inhibitor of cystine/
glutamate antiporter [25,26], significantly reduced gluta-
mate release by LPS-activated monocytes (n =4 ;p = 0.02;
Figure 1A), indicating that the xc
- system is the main glu-
tamate release mechanism in monocytes. Accordingly,
intracellular glutathione levels were increased after LPS
treatment (n = 3; p = 0.03; Figure 1B), as a result of an
increased function of xCT antiporter.
Finally, 6-diazo-5-oxo-L-norleucine (DON; 1 mM), an
inhibitor of glutaminase enzyme, also inhibited signifi-
cantly glutamate release by monocytes (n =4 ;p =0 . 0 2 ;
Figure 1A). Glutaminase is the key enzyme to replenish
glutamate pool in neuronal presynaptic terminals. Simi-
larly, it is possible that blocking glutaminase in mono-
cytes depletes the pool of glutamate that is released
after their activation with LPS.
Activation of human monocytes with LPS upregulates
cystine/glutamate antiporter expression
Because the system xc
- is modulated by oxidative stress
[27], we next examined whether LPS modulated system
xc
- expression in monocytes. System xc
- is a heteromeric
protein complex consisting on a catalytic L chain (xCT)
and a regulatory H chain (4F2hc) [27]. In control
patients, the levels of xCT in CD14
+ monocytes are
much higher than the levels of the major glutamate
transporters EAAT1 and EAAT2 (Figure 1C). We then
analyzed the expression of xCT in U-937 cells after
their activation with LPS (1 μg/ml, 48 h) by quantitative
PCR (qPCR) and Western blot. LPS activation (1 μg/ml)
i n d u c e da ni n c r e a s ei nx C Tm R N Ae x p r e s s i o n( n =5 ;
p = 0.014; Figure 1D). Accordingly, Western blot analy-
sis revealed a two-fold increase in xCT protein levels
(n =3 ;p = 0.01; Figure 1E). Upregulation of xCT
expression is not secondary to glutamate homeostasis
alteration since the incubation with glutamate (100 μM
to 1 mM; 48 h) did not change xCT mRNA expression
(n=3 ; Figure 1F), suggesting that extracellular gluta-
mate increase is correlative, not causative, of xCT upre-
gulation. In addition, the expression of other enzymes
involved in glutamate metabolism, such as glutamine
synthetase, was not change after LPS treatment (Figure
1D). Similar to LPS, activation with TNFa also induced
an increase in xCT mRNA expression (Figure 1F).
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Page 5 of 12Figure 1 Activated U-937 monocytes release glutamate through cystine/glutamate antiporter and show an increased expression of
the xCT subunit. A. Glutamate release by U-937 cells after activation with LPS (1 μg/ml) for 48 h in the absence and in the presence of the
inhibitor of cystine/glutamate antiporter, AAA (1 mM), the glutaminase inhibitor DON (1 mM) and the inhibitors of glutamate transporters, DHK
(1 mM), and TBOA (100 μM). Ordinates indicate the difference between the amount of glutamate released by LPS-activated and resting
monocytes. Data are mean ± SEM from 4 independent experiments performed in triplicate. B, Intracellular glutathione levels in control U-937
cells and after activation with LPS (1 μg/ml) for 48 h. C. Relative expression of xCT antiporter and glutamate transporters EAAT1, EAAT2 and
EAAT3 in CD14
+ monocytes. D. Histogram illustrates the increase of xCT mRNA expression, but not of glutaminase (GLS), in LPS-activated U-937
monocytes using qPCR. U-937 cells were treated with LPS (1 μg/ml) for 48 h and qPCR data were normalized using 4 housekeeping genes and
GeNorm software. Data are mean ± SEM from 3 independent experiments performed in triplicate. E. Western blotting analysis shows an up-
regulation of xCT protein in U-937 cells after LPS (1 μg/ml) treatment for 48 ch. Data were normalized to actin and expressed as mean ± SEM
from 3 independent experiments performed in triplicate. F. xCT mRNA levels in U-937 monocyte cell line increase after LPS (1 μg/ml) treatment
but not after incubation with glutamate (100 μM and 1 mM) for 48 h. Stimulation with the cytokine TNFa (10 ng/ml; 24 h) also induced a
significant increase in xCT mRNA expression. qPCR data were normalized using 4 housekeeping genes and GeNorm software. Data are mean ±
SEM from 3 independent experiments performed in triplicate. *, p < 0.05; **, p < 0.01.
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enhances xCT expression and function in U-937 mono-
cyte cell line.
We then examined if the aforementioned features are
also present in blood monocytes freshly isolated by
MACS. After isolation, cells were maintained in culture
for 96 h and subsequently activated with LPS (1 μg/ml,
48 h). Similarly to U-937 cell line, monocytes showed an
increase of 33.5% in glutamate levels after their activa-
tion with LPS (p = 0.04; Figure 2A), which was blocked
in the presence of AAA (n = 3; p = 0.01; Figure 2A). To
confirm changes in xCT expression in LPS-activated
human monocytes we carried out flow cytometry analy-
sis. LPS-treated monocytes, not lymphocytes, showed a
change in the granularity, a parameter indicative of the
activated state of monocytes (Figure 2B left-up). The
analysis of xCT expression was performed by gating
CD14
+ monocytes. Staining cells with xCT antibodies
showed a clear shift versus the IgG isotype control, indi-
cating that the staining with this antibody was specific
(Figure 2B left-bottom). Similar to the results obtained
in the U-937 cell line, there was an increase in xCT
expression in CD14
+ cells after their activation with LPS
(n =5 ;p = 0.0098; Figure 2B right). Thus, LPS activa-
tion also enhances xCT expression and function in per-
ipheral blood monocytes.
xCT expression is increased in EAE
S i n c eg l u t a m a t el e v e l sa r er e p o r t e dt ob ea l t e r e di nM S
disease [12,13,28] and monocyte infiltration and micro-
glial activation are MS hallmarks [29], we hypothesized
that the expression of system xc
- could be altered in MS
disease. To test this hypothesis, we analyzed the expres-
sion of xCT in the spinal cord of rats after induction of
acute EAE, an experimental model of MS which repro-
duces the inflammatory and immune component of the
disease.
Rats immunized with myelin basic protein showed
maximal motor deficits at around 14 days postimmuni-
z a t i o n( F i g u r e3 A ) .A tt h a ts t a g e ,e x p r e s s i o no fm R N A
encoding xCT was more abundant in spinal cord sam-
ples from rats with EAE than in control animals (n =6 ;
p = 0.013; Figure 3B left). Accordingly, xCT protein
levels were significantly increased in EAE rats (n = 5; p
< 0.05; Figure 3B right). We also analysed the expression
of xCT in the spinal cord by double immunofluores-
cence using antibodies to OX-42, a marker of microglia
lineage. No immunolabeling was detected after preincu-
bation xCT antibodies with the corresponding peptide
(Additional file 3, Figure S2), demonstrating the specifi-
city of the immunofluorescence signal. xCT expression
was dramatically increased in the spinal cord of rats
with EAE. The expression was particularly increased in
meninges in EAE animals, showing clear signs of inflam-
mation (asterisk in Figure 3C top right). There was also
a clear increase of xCT in OX42
+ infiltrating cells,
which were organized in clusters around vessels (Figure
3C bottom). In addition, activated microglial cells in
EAE rats showed a massive upregulation of xCT (Figure
3D). Activated microglia was identified by their charac-
teristic ameboid shape in contrast with the ramified
appearance of resting microglia in control animals
(arrows in Figure 3D). Increases in xCT expression at
the level of RNA and protein were also detected in the
chronic EAE mice (n = 5 for RNA and protein; p <
0.05; Figure 3E), a model that reproduces the chronic
and progressive phase of MS.
xCT expression is increased in MS
We next checked whether system xc
- expression is simi-
larly altered in MS disease. We analyzed the expression
of xCT in peripheral blood and in postmortem optic
Figure 2 Activation of human peripheral blood monocytes by
LPS induces glutamate release through the cystine/glutamate
antiporter and xCT upregulation. A. Monocytes, isolated by
MACS, showed an increase in glutamate release after their activation
with LPS (1 μg/ml, 48 h). This effect is prevented in the presence of
AAA (1 mM), an inhibitor of the cystine/glutamate antiporter. B.
Flow cytometry analysis of peripheral blood monocytes (CD14-PE)
reveals a change in the morphology of monocyte population after
their activation with LPS (left-up). Staining with xCT-FITC
demonstrates higher expression of this exchanger in LPS-activated
CD14
+ monocytes (left-down and right). *, p < 0.05; **, p < 0.01; #,
p < 0.05 vs. LPS treatment.
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Page 7 of 12Figure 3 xCT expression is increased in the CNS of rats with EAE. A. Histogram showing the neurological score during the course of acute
EAE induced in Lewis rats by immunization with myelin basic protein. The peak of neurological disability was at day 14 post-immunization,
which was selected for obtaining tissue samples. B. xCT mRNA (left) and protein (right) expression in spinal cord from control and acute EAE rats,
as assessed by qPCR and Western blot analysis. Data are referred to mean expression level of controls (n = 5-6). C. Double immunofluorescence
for xCT (green) and OX-42 (red), a marker of microglia and infiltrating macrophages. OX42
+ cells express high xCT levels in acute EAE. Both
meninges (asterisk in top) and infiltrating cells (bottom) in inflammatory foci show high levels of xCT in rat spinal cord with EAE as compared to
controls. D. Microglial cells (OX42
+ cells) of EAE rats have higher xCT levels in spinal cord than controls. Notice the difference between resting
microglia in control rats, with ramified morphology (arrows in control) and microglia in EAE showing round shaped morphology, characteristic of
its activated state (arrows in EAE). Scale bar = 20 μm.E. xCT mRNA (left) and protein (right) expression in spinal cord from control and chronic
EAE mice, assessed by qPCR and Western blot analysis. Data are referred to mean expression level of controls (n = 5).
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xCT mRNA levels showed a 2.5 average fold increase in
isolated leukocytes from MS patients (n = 52) compared
to controls (n = 25; p =0 . 0 0 3 ;F i g u r e4 A ) .I nt u r n ,t h e
increase in xCT levels was higher in R-MS patients hav-
ing a clinical relapse (n = 24; p = 0.016; Figure 4A) than
during remission (n = 28; p =0 . 0 5 5 ;F i g u r e4 A ) .E l e -
vated xCT expression was also observed in CNS sam-
ples. Thus, the levels of xCT mRNA in optic nerve
(ON) from MS patients showed a two fold increase
compared to matched controls (n =1 6 ;p = 0.027; Fig-
ure 4B). The increase in xCT mRNA expression was sig-
nificantly higher in damaged optic nerves showing
macroscopic plaques, atrophy and/or optic neuritis.
Moreover, levels of xCT mRNA showed a high correla-
tion with CD8 mRNA (Pearson r = 0.83; n = 16; p =
0.0013, Figure 1C), a marker of infiltration and lympho-
cyte activity, suggesting that lesion activity correlates
with xCT expression. Interestingly, the levels of xCT
expression in the ON of MS patients correlated posi-
tively with the levels of EAAT2 reported previously [21]
(Pearson r =0 . 8 1 ;n = 10; p = 0.005; Figure 1D).
Because an enhanced xCT expression is associated to an
increase in extracellular glutamate in monocytes in
vitro, the increase in glutamate transporter expression
could be an adaptive response to counteract the excess
of glutamate driven by xCT in MS.
Finally, we performed double immunofluorescence
analysis of xCT expression in the spinal cord of MS
patients and controls. Overall, we observed a higher
expression of xCT in the CNS of MS patients than in
controls. In particular, infiltrating CD68
+ macrophages
revealed higher xCT expression in MS patients than in
controls (Figure 5). Thus, CD68
+ cells located in blood
vessels (Figure 5A) or nearby, and usually forming clus-
ters, showed a clear xCT overexpression in MS patients
Figure 4 xCT mRNA expression is increased in MS patients. A. Data show a significant increase in xCT mRNA expression in leukocytes in
relapsing-MS, which is more prominent during relapses. Controls, n = 39; Total R-MS, n = 42; R-MS in remission, n = 24; R-MS in relapse, n = 18.
B. Data show a significant increase in xCT mRNA in human optic nerve from MS patients as compared to matched controls. Damage optic
nerves (DON), showing macroscopic plaques, atrophy and/or optic neuritis have a significantly higher increase in xCT mRNA. *, p < 0.05; **, p <
0.01; #, p < 0.05. C, D. xCT mRNA expression correlates with CD8 and EAAT2 mRNA expression in MS optic nerve. Pearson r = 0.83; n = 10; p =
0.0013 for CD8 vs. xCT. Pearson r = 0.81; n = 10; p = 0.005 for EAAT2 vs. xCT.
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increase of xCT expression in EAE animals, and suggest
that altered xCT expression may have a pathophysiolo-
gical role in MS disease.
Discussion
I nt h ec u r r e n ts t u d yw eh a v es h o w nt h a tb l o o dm o n o -
cytes release glutamate through the xc
- system and that
its constitutive expression and function is upregulated
by activation with LPS. In addition, we provide evidence
that xCT expression is increased in activated macro-
phages-microglia in the CNS, both in EAE and in MS,
as well as in leukocytes from MS patients.
The findings described here point to system xc
- as a
major glutamate release mechanism in activated mono-
cytes. This is consistent with previous observations illus-
trating the expression of the xc
- system in microglia [22]
and macrophages [25,30]. Importantly, we show that the
increase in glutamate release after the inflammatory sti-
mulus is due to an elevation in the expression of xCT,
the catalytic subunit of the system xc
-, which is constitu-
tively expressed in human monocytes. These results are
in keeping with other studies reporting that mouse
macrophages induce xc
- expression in response to both
LPS and oxygen [31-33], a mechanism that allows replen-
ishment of the glutathione pool during inflammatory
conditions and oxidative stress. Glutamate did not
change xCT expression by itself, excluding the possibility
that xCT expression changes could be adaptive changes
to extracellular glutamate accumulation. Altogether, the
expression of the xc
- system in monocyte-macrophage-
microglia lineage provides a direct link between gluta-
mate homeostasis alteration and inflammation.
We also provide evidence that, like in neurons, gluta-
minase is a key enzyme to replenish the glutamate pool
necessary to efficiently release glutamate in monocytes.
In accordance, other studies have reported that inhibition
of glutaminase prevents from glutamate release in acti-
vated microglia [34,35]. Interestingly, glutaminase expres-
sion is increased in macrophages and microglia that are
close to dystrophic axons in active MS lesions [36], sug-
gesting a possible role of this enzyme in glutamate home-
ostasis alteration and MS pathophysiology. Indeed, the
implication of enhanced glutaminase expression and
activity in MS is sustained by the fact that its inhibition
attenuates EAE clinical symptoms, possibly by diminish-
ing oligodendroglial cell death and axonal damage since
inflammatory cell infiltration is not reduced [37].
We observed an increased xCT expression in OX-42
+
cells (microglia, meningeal cells and dendritic cells) in
the spinal cord of rats with acute EAE. Meninges con-
stitutively express xCT, which contributes to the main-
tenance of the redox state by recycling cystine to
cysteine in the CSF and plasma [38]. In addition, cellu-
lar infiltrates, which are typically composed by infiltrat-
ing macrophages and dendritic cells [17], and usually
enter the CNS through blood vessels [39], also showed
higher xCT level in EAE. Finally, resident microglia,
Figure 5 xCT expression is enhanced in CD68
+ cells from MS spinal
cord. A. Triple immunofluorescence staining for xCT (green), CD68 (red)
and Hoechst 33258 (blue) in spinal cord of control (left) and MS patients
(right). A high expression of xCT was detected in CD68
+ infiltrating
macrophages (arrows) associated with blood vessels, which are virtually
absent in controls. Note that overall xCT expression is enhanced in MS
tissue. B. CD68
+ cells (arrows) show enhanced xCT expression in MS
patients as compared to controls. CD68
+ macrophages are round
shaped and form clusters in MS patients, whereas in controls, CD68
+
cells appear isolated and long shaped. Scale bar = 50 μm.
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+ staining and by their charac-
teristic rounded morphology indicative of activated
state, showed a clear increase of xCT during EAE. Alto-
gether, xCT overexpression in OX-42
+ cells during
EAE, may serve to counteract oxidative stress during
inflammatory conditions. However, an increased uptake
of cystine leads to an enhanced glutamate release,
which could have negative consequences to oligoden-
droglial survival. Indeed, an enhanced activity of xc
- sys-
tem secondary to microglial activation has been
reported to induce oligodendrocyte cell death by gluta-
mate receptor overstimulation [22].
Consistent with the findings in the EAE model, MS
patients show an increased xCT expression in spinal cord
macrophages which are located in blood vessels and form
cell clusters. Moreover, higher xCT expression in leuko-
cytes during the course of MS relapses suggests dynamic
changes in response to inflammatory activity. An increased
expression of xCT or an altered function of xc
- system has
been described in other CNS disorders [40]. In malignant
brain tumors, glutamate release by glioma cells through
the xc
- system contributes to glioma-induced peritumoral
cell death, and inhibition of its activity lessens neurode-
generation and alleviates perifocal edema [41]. In addition,
an increased expression of xCT has been described in an
animal model of Parkinson’s disease [42] and in reactive
microglia located in amyloid plaques of transgenic mice
expressing mutant human amyloid precursor protein, as
well as in wild-type mice injected with amyloid-b [26].
Altogether data indicate that xc
- system expression is
altered as a consequence of inflammation and oxidative
stress in CNS disorders with an important inflammatory
component. Because system xc
- plays an essential role in
the antioxidant defense of the cell [38,43], more detailed
studies are needed to determine whether the system con-
stitutes a new therapeutic target for these disorders.
Conclusions
This study provides the first evidence that activated
monocytes/macrophages/microglia release glutamate
through cystine/glutamate antiporter by increasing xCT
expression, as assessed by in vitro assays as well as in
both EAE and MS. These findings support the idea that
system xc
- acts as a link between inflammation and glu-
tamate excitotoxicity, and that xCT is a potential target
to attenuate glutamate excitotoxicity in neurodegenera-
tive diseases undergoing inflammation.
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